RAS mutations predict a lack of response in patients with metastatic colorectal cancer who receive panitumumab–FOLFOX4

Patients with metastatic colorectal cancer and KRAS mutations in exon 2 do not benefit from anti-EGFR therapy. However, other activating RAS mutations may predict poorer outcome with anti-EGFR therapy. In a prospectively planned retrospective biomarker analysis from the PRIME study, reported in The New England Journal of Medicine by Dr Jean-Yves Douillard of Institut René Gauducheau, who is currently a Chair of the ESMO Educational Committee, and colleagues, the addition of panitumumab to FOLFOX4 regimen was associated with improved progression-free survival and overall survival in patients without RAS mutations. Read more here.

Study mentioned: Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013 Sep 12;369(11):1023-34. PMID: 24024839